eligibility_summary
Adults ≥18 with relapsed/locally advanced/metastatic esophageal carcinoma or other solid tumors, ≥1 measurable non-cavity lesion (RECIST 1.1), provide tumor/blood, ECOG 0–1, life expectancy >12 weeks, contraception, not pregnant, consent. Exclude: prior B7‑H3, recent chemo/biologic/RT/major surgery, other malignancies, high‑risk invasion, marrow/organ dysfunction, CV risk, uncontrolled disease, bleeding/infections, active HBV/HCV, neuropathy/mental disorders, hypersensitivity/vaccine, pregnancy/lactation, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests HS-20093, a humanized IgG1 antibody-drug conjugate (ADC) given IV every 3 weeks. Mechanism: HS-20093 binds B7-H3 (CD276) on tumor cells, is internalized, and releases a cytotoxic payload to induce tumor cell death, its IgG1 Fc may also mediate immune effector functions (e.g., ADCC/ADCP). Target cells/pathways: B7-H3–expressing solid tumors, including esophageal squamous cell carcinoma, esophageal adenocarcinoma/GEJ adenocarcinoma, and other advanced solid tumors. B7-H3 is a B7 family immune checkpoint molecule broadly overexpressed on tumor cells and in the tumor microenvironment, the ADC leverages this expression to selectively deliver cytotoxic therapy to malignant cells. The study evaluates antitumor activity, safety, PK, and immunogenicity in Chinese patients.